Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $143
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Abbott Laboratories (NYSE:ABT) and raises the price target from $140 to $143.
July 29, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Matt Miksic maintains an Overweight rating on Abbott Laboratories and raises the price target from $140 to $143.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for Abbott Laboratories.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100